Comparison of Adverse Events between Diphenhydramine and Levocetirizine Pretreatment in Multiple Myeloma Patients Treated with Subcutaneous Daratumumab-Reference-Cited by-同舟云学术

Comparison of Adverse Events between Diphenhydramine and Levocetirizine Pretreatment in Multiple Myeloma Patients Treated with Subcutaneous Daratumumab

Published:2023-08-10 Issue:8 Volume:49 Page:303-309
ISSN:1346-342X
Container-title:Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
language:en
Short-container-title:Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)

Author:

Suehiro Naoya¹,Nagashima Ayano¹,Nishikawa Haru¹,Suzukawa Mayu²,Sakurai Hiroomi¹,Muramatsu Hiroshi¹,Aomori Toru¹²³,Ohtani Hisakazu¹²³

Affiliation:

1. Department of Pharmacy, Keio University Hospital

2. Keio University Faculty of Pharmacy

3. Keio University School of Medicine

Publisher

Japanese Society of Pharmaceutical Health Care and Sciences

Link

https://www.jstage.jst.go.jp/article/jjphcs/49/8/49_303/_pdf

Reference16 articles.

1. 1）日本骨髄腫学会, “多発性骨髄腫の診療指針”, 第5版, 文光堂, 東京, 2020, pp2-4.

2. 2）Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Murphy S, Lutska Y, Pei H, Ukropec J, Vermeulen J, de Boer C, Hoehn D, Lin TS, Richardson PG, Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma, N Engl J Med, 2016, 375, 1319-1331.

3. 3）Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P, Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma, N Engl J Med, 2016, 375, 754-766.

4. 4）Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM, Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIU): an open-label, randomized, phase 2 trial, Lancet, 2016, 387, 1551-1560.

5. 5）Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis N, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Clemens PL, Masterson T, Lantz K, O’Rourke L, Heuck C, Qin X, Parasrampuria DA, Yuan Z, Xu S, Qi M, Usmani SZ, Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomized, phase 3 trial, Lancet Haematol, 2020, 7, e370-e380.